Skip to main content
main-content
Erschienen in: Die Diabetologie 5/2022

30.06.2022 | Periphere arterielle Verschlusskrankheit | Leitthema

Periphere arterielle Verschlusskrankheit bei Menschen mit Diabetes

verfasst von: Dr. Holger Lawall

Erschienen in: Die Diabetologie | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Durch die Zunahme des Diabetes mellitus und die Alterung der Gesellschaft steigt die Zahl der Patienten mit Diabetes und pAVK (periphere arterielle Verschlusskrankheit) kontinuierlich an. Diabetes ist ein Hauptrisikofaktor für die Entstehung und Progression der pAVK, und die Kombination beider Erkrankungen verschlechtert die Prognose der Betroffenen. Wichtig sind die rechtzeitige Diagnostik und die dem klinischen Stadium angemessene Therapie.
Wie bei anderen atheromatösen Gefäßerkrankungen ist die Behandlung der vaskulären Risikofaktoren essenziell. Grundpfeiler der Therapie sind strukturierter Gefäßsport, Plättchenhemmer und Statine. Die Kombination von ASS (Azetylsalizylsäure) und Rivaroxaban erweitert die Behandlungsoptionen bei vaskulären Hochrisikopatienten. Bei Menschen mit Diabetes sind die Langzeitergebnisse der Revaskularisation oft unbefriedigend, deshalb ist besonders im Stadium der Claudicatio die Indikation zu dieser Maßnahme eng zu stellen. Bei kritischer extremitätenbedrohender Ischämie müssen dagegen umgehend ein Gefäßmediziner konsultiert und eine schnellstmögliche Revaskularisation angestrebt werden.
Literatur
1.
Zurück zum Zitat Song P, Rudan D, Zhu Y et al (2019) Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health 7:e1020–e1030 CrossRef Song P, Rudan D, Zhu Y et al (2019) Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health 7:e1020–e1030 CrossRef
3.
Zurück zum Zitat Kreutzburg T, Peters F, Rieß HC et al (2020) Comorbidity patterns among patients with peripheral arterial occlussive disease in Germany: a trend analysis of health insurance claims data. Eur J Vasc Endovasc Surg 59:59–66 CrossRef Kreutzburg T, Peters F, Rieß HC et al (2020) Comorbidity patterns among patients with peripheral arterial occlussive disease in Germany: a trend analysis of health insurance claims data. Eur J Vasc Endovasc Surg 59:59–66 CrossRef
4.
Zurück zum Zitat Stoberock K, Kaschwich M, Nicolay SS et al (2021) The interrelationship between diabetes and peripheral arterial disease—A systematic review. Vasa 50:323–330 CrossRef Stoberock K, Kaschwich M, Nicolay SS et al (2021) The interrelationship between diabetes and peripheral arterial disease—A systematic review. Vasa 50:323–330 CrossRef
5.
Zurück zum Zitat Baubeta FE, Andersson M, Thuresson M et al (2018) Editor’s choice-impact of comorbidity, medication, and gender on amputation rate following revascularization for chronic limb threatening ischemia. Eur J Vasc Endovasc Surg 56:681–688 CrossRef Baubeta FE, Andersson M, Thuresson M et al (2018) Editor’s choice-impact of comorbidity, medication, and gender on amputation rate following revascularization for chronic limb threatening ischemia. Eur J Vasc Endovasc Surg 56:681–688 CrossRef
7.
Zurück zum Zitat Goldman MP, Corriere MA, Craven T et al (2021) Evaluation of neuropathy, gylcemic control, and revascularization as risk factors for future lower extremity amputation among diabetic patients. Ann Vasc Surg 73:254–263 CrossRef Goldman MP, Corriere MA, Craven T et al (2021) Evaluation of neuropathy, gylcemic control, and revascularization as risk factors for future lower extremity amputation among diabetic patients. Ann Vasc Surg 73:254–263 CrossRef
8.
Zurück zum Zitat Freisinger E, Malyar NM, Reinecke H, Lawall H (2017) Impact of diabetes on outcome in critical limb ischemia with tissue loss: a large-scaled routine data analysis. Cardiovasc Diabetol 16:1–10 CrossRef Freisinger E, Malyar NM, Reinecke H, Lawall H (2017) Impact of diabetes on outcome in critical limb ischemia with tissue loss: a large-scaled routine data analysis. Cardiovasc Diabetol 16:1–10 CrossRef
9.
Zurück zum Zitat Forsythe RO, Apelquist J, Boyko EJ et al (2020) Effectiveness of bedside investigations to diagnose peripheral artery disease among people with diabetes mellitus: A systematic review. Diab Met Res Rev 36(S1):e3277 Forsythe RO, Apelquist J, Boyko EJ et al (2020) Effectiveness of bedside investigations to diagnose peripheral artery disease among people with diabetes mellitus: A systematic review. Diab Met Res Rev 36(S1):e3277
10.
Zurück zum Zitat Thanigaimani S, Phie J, Sharma C et al (2021) Network meta-analysis comparing the outcomes of treatments for intermittent claudication tested in randomized controlled trials. J Am Heart Ass 10(9):e19672 CrossRef Thanigaimani S, Phie J, Sharma C et al (2021) Network meta-analysis comparing the outcomes of treatments for intermittent claudication tested in randomized controlled trials. J Am Heart Ass 10(9):e19672 CrossRef
12.
Zurück zum Zitat Djerf H, Millinger J, Falkenberg M et al (2020) Absence of long-term benefit of revascularisation in patients with intermittent claudication: five-year results from the IRONIC randomized controlled trial. Circ Cardiovasc Interv 13(1):e8450 CrossRef Djerf H, Millinger J, Falkenberg M et al (2020) Absence of long-term benefit of revascularisation in patients with intermittent claudication: five-year results from the IRONIC randomized controlled trial. Circ Cardiovasc Interv 13(1):e8450 CrossRef
13.
Zurück zum Zitat Jansen SC, Hoorweg B, Hoeks S et al (2019) A systematic review and meta-analysis of the effects of supervised exercise therapy on modifiable cardiovascular risk factors in intermittent claudication. J Vasc Surg 69:1293–1308 CrossRef Jansen SC, Hoorweg B, Hoeks S et al (2019) A systematic review and meta-analysis of the effects of supervised exercise therapy on modifiable cardiovascular risk factors in intermittent claudication. J Vasc Surg 69:1293–1308 CrossRef
15.
Zurück zum Zitat Dakhel A, Zarrouk M, Ekelund J et al (2021) Long-term cardiovascular morbidity after open surgery for intermittent claudication caused by infrainguinal atherosclerotic disease in patients with diabetes: a nationwide observational cohort study. Vasa 50:224–230 CrossRef Dakhel A, Zarrouk M, Ekelund J et al (2021) Long-term cardiovascular morbidity after open surgery for intermittent claudication caused by infrainguinal atherosclerotic disease in patients with diabetes: a nationwide observational cohort study. Vasa 50:224–230 CrossRef
16.
Zurück zum Zitat Rongzhou H, Yanchen Y, Zilun L et al (2019) Restenosis prevention with drug eluting or covered stents in femoropopliteal arterial occlusive disease: evidence from a comprehensive network meta-analysis. Eur J Vasc Endovasc Surg 58:61–74 CrossRef Rongzhou H, Yanchen Y, Zilun L et al (2019) Restenosis prevention with drug eluting or covered stents in femoropopliteal arterial occlusive disease: evidence from a comprehensive network meta-analysis. Eur J Vasc Endovasc Surg 58:61–74 CrossRef
18.
Zurück zum Zitat Almasri J, Adusumalli J, Asi N et al (2019) A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg 58((Suppl 1):110–119 CrossRef Almasri J, Adusumalli J, Asi N et al (2019) A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg 58((Suppl 1):110–119 CrossRef
19.
Zurück zum Zitat Dayama A, Tsilimparis N, Kolakowski S et al (2019) Clinical outcomes of bypass-firstversus endovascular-first strategy in patients with chronic limb-threatening ischemia due to infrapopliteal arterial disease. J Vasc Surg 69:156–163 CrossRef Dayama A, Tsilimparis N, Kolakowski S et al (2019) Clinical outcomes of bypass-firstversus endovascular-first strategy in patients with chronic limb-threatening ischemia due to infrapopliteal arterial disease. J Vasc Surg 69:156–163 CrossRef
20.
Zurück zum Zitat Korosoglou G, Giusca S, Langhoff R et al (2022in) Safety and effectiveness of endovascular therapy for the treatment of peripheral artery disease in patients with and without diabetes mellitus: data from thr REcording courses of vascular diseases (RECCORD) registry in 2123 patients. Int Angiol (in press) Korosoglou G, Giusca S, Langhoff R et al (2022in) Safety and effectiveness of endovascular therapy for the treatment of peripheral artery disease in patients with and without diabetes mellitus: data from thr REcording courses of vascular diseases (RECCORD) registry in 2123 patients. Int Angiol (in press)
22.
Zurück zum Zitat Ambler GK, Waldron CA, Contractor UB et al (2020) Umbrella review and meta-analysis of antiplatelet therapy for peripheral artery disease. BMS 107:20–32 Ambler GK, Waldron CA, Contractor UB et al (2020) Umbrella review and meta-analysis of antiplatelet therapy for peripheral artery disease. BMS 107:20–32
23.
Zurück zum Zitat Savarese G, Reiner MF, Uiil A et al (2020) Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the ESC Working Group. Eur Heart J Cardiovasc Pharmcother 6:86–93 CrossRef Savarese G, Reiner MF, Uiil A et al (2020) Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the ESC Working Group. Eur Heart J Cardiovasc Pharmcother 6:86–93 CrossRef
24.
Zurück zum Zitat Bonaca MP, Bauersachs RM, Anand S et al (2020) Rivaroxaban in peripheral artery disease after revascularisation. N Engl J Med 382:1994–2004 CrossRef Bonaca MP, Bauersachs RM, Anand S et al (2020) Rivaroxaban in peripheral artery disease after revascularisation. N Engl J Med 382:1994–2004 CrossRef
25.
Zurück zum Zitat Bhatt DL, Eikelboom JW, Connolly SJ et al (2020) Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease: insights from the COMPASS trial. Circulation 141:1841–1854 CrossRef Bhatt DL, Eikelboom JW, Connolly SJ et al (2020) Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease: insights from the COMPASS trial. Circulation 141:1841–1854 CrossRef
26.
Zurück zum Zitat Hsu CY, Chen YT, Su YW et al (2017) Statin therapy reduces furture risk of lower-limb amputation in patients with diabetes and peripheral artery disease. J Clin Endocrinol Metab 102:2373–2381 CrossRef Hsu CY, Chen YT, Su YW et al (2017) Statin therapy reduces furture risk of lower-limb amputation in patients with diabetes and peripheral artery disease. J Clin Endocrinol Metab 102:2373–2381 CrossRef
27.
Zurück zum Zitat Arya S, Khakharia A, Binney ZO et al (2018) Association of statin dose with amputation and survival in patients with peripheral artery disease. Circulation 137:1435–1446 CrossRef Arya S, Khakharia A, Binney ZO et al (2018) Association of statin dose with amputation and survival in patients with peripheral artery disease. Circulation 137:1435–1446 CrossRef
28.
Zurück zum Zitat Bonaca MP, Nault P, Giugliano RP et al (2018) Low density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial. Circulation 137:338–350 CrossRef Bonaca MP, Nault P, Giugliano RP et al (2018) Low density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial. Circulation 137:338–350 CrossRef
29.
Zurück zum Zitat Hinchliffe RJ, Forsythe RO, Apelqvist J et al (2020) Guidelines on diagnosis, prognosis, and management of peripheral artery disease in patients with foot ulcers and diabetes (IWGDF 2019 update). Diabetes Metab Res Rev 36:e3276 CrossRef Hinchliffe RJ, Forsythe RO, Apelqvist J et al (2020) Guidelines on diagnosis, prognosis, and management of peripheral artery disease in patients with foot ulcers and diabetes (IWGDF 2019 update). Diabetes Metab Res Rev 36:e3276 CrossRef
30.
Zurück zum Zitat Cosentino F, Grant PJ, Aboyans V et al (2020) ESC Scientific Document Group. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41:255–323 CrossRef Cosentino F, Grant PJ, Aboyans V et al (2020) ESC Scientific Document Group. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41:255–323 CrossRef
31.
Zurück zum Zitat Balletshofer B, Böckler D, Diener H et al (2021) Position paper on the diagnosis and treatment of peripheral arterial disease (PAD) in people with diabetes mellitus. Diab Stoffw 16(Suppl 2):351–362 Balletshofer B, Böckler D, Diener H et al (2021) Position paper on the diagnosis and treatment of peripheral arterial disease (PAD) in people with diabetes mellitus. Diab Stoffw 16(Suppl 2):351–362
Metadaten
Titel
Periphere arterielle Verschlusskrankheit bei Menschen mit Diabetes
verfasst von
Dr. Holger Lawall
Publikationsdatum
30.06.2022
Verlag
Springer Medizin
Erschienen in
Die Diabetologie / Ausgabe 5/2022
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI
https://doi.org/10.1007/s11428-022-00931-3

Weitere Artikel der Ausgabe 5/2022

Die Diabetologie 5/2022 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.